Bedaquiline: what might the future hold?

Emily S. Shaw, Neil G. Stoker, Jessica L. Potter, Helgard Claassen, Alasdair Leslie, Conor D. Tweed, Chen Yuan Chiang, Francesca Conradie, Hanif Esmail, Christoph Lange, Lancelot Pinto, Oxana Rucsineanu, Derek J. Sloan, Grant Theron, Phumeza Tisile, Teck Chuan Voo, Robin M. Warren, Limakatso Lebina, Marc Lipman

研究成果: 雜誌貢獻回顧型文獻同行評審

摘要

Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have transformed the treatment of drug-resistant tuberculosis, offering safer and more effective oral treatment options. However, key obstacles need to be overcome to ensure global access and prevent the rapid development of resistance against this promising class of drugs. In this Personal View, building on an international workshop held in 2023, we evaluate the current evidence and suggest possible ways forward, recognising the tension between increasing use and slowing the rise of resistance. We also discuss problems in accessing bedaquiline-containing regimens, the potential widening of their use beyond drug-resistant tuberculosis, and lessons for utilising new drugs as they are developed.
原文英語
文章編號100909
期刊The Lancet Microbe
DOIs
出版狀態接受/付印 - 2024

ASJC Scopus subject areas

  • 微生物學
  • 微生物學(醫學)
  • 傳染性疾病
  • 病毒學

指紋

深入研究「Bedaquiline: what might the future hold?」主題。共同形成了獨特的指紋。

引用此